← Leaderboards
Francis C Szoka
University Of California San Francisco
$17,593,815
Attributed
$17,593,815
Total exposure
34
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–15$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$17,593,815 · 34
By mechanism
R01$12,370,808 · 7
T32$2,721,461 · 1
R21$1,201,346 · 3
U54$613,684 · 1
P41$387,596 · 21
R41$298,920 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Amy M Barrios$3,535,800
- Dane M Chetkovich$15,281,051
- Stephen B Kahl$7,278,768
- Thomas L James$6,218,651
- Stanley B Prusiner$54,781,835
Others in their field
Top investigators on “Drug Delivery Systems”
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Gerald Van Belle · University Of Washington$48,120,734
- David Heimbrook · Leidos Biomedical Research, Inc.$47,325,954
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$38,382,452
- Martin Friedlander · Scripps Research Institute$36,319,942
Research focus
Drug Delivery SystemsLiposomesLigandsCellsTumorPropertyLipidsPharmaceutical PreparationsMalignant NeoplasmsDesignFundingPolymersLeadSuccessBaseSurfaceMediatingDrug FormulationsGenesIn VivoCd44 GeneHyaluronanNeoplastic CellEsters
Grant awards (90)
Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells$298,920
R41 · FY2015 · CA · contact PI
Targeted Drug Delivery to Surface Receptors.$298,567
R01 · FY2015 · GM · contact PI
Syngeneic Macrophages for Personalized Cancer Therapy$172,097
R21 · FY2015 · CA · contact PI
Targeted Drug Delivery to Surface Receptors.$298,567
R01 · FY2014 · GM · contact PI
Syngeneic Macrophages for Personalized Cancer Therapy$201,235
R21 · FY2014 · CA · contact PI
Rational Design of Viral-Mimetic Lipid Gene Vectors$309,216
R01 · FY2013 · EB · contact PI
Targeted Drug Delivery to Surface Receptors.$288,117
R01 · FY2013 · GM · contact PI
Improving Protein Delivery and Circulation via FcRn Ligands$176,537
R21 · FY2013 · EB · contact PI
Rational Design of Viral-Mimetic Lipid Gene Vectors$327,906
R01 · FY2012 · EB · contact PI
Targeted Drug Delivery to Surface Receptors.$298,567
R01 · FY2012 · GM · contact PI
HIV neutralizing antibodies induced by chemically modified MPR epitopes$231,750
R21 · FY2012 · AI · contact PI
Improving Protein Delivery and Circulation via FcRn Ligands$226,602
R21 · FY2012 · EB · contact PI
Rational Design of Viral-Mimetic Lipid Gene Vectors$35,000
R01 · FY2012 · EB · contact PI
Targeted Drug Delivery to Surface Receptors.$21,440
R01 · FY2012 · GM · contact PI
Rational Design of Viral-Mimetic Lipid Gene Vectors$327,906
R01 · FY2011 · EB · contact PI
HIV neutralizing antibodies induced by chemically modified MPR epitopes$193,125
R21 · FY2011 · AI · contact PI
DRUG AND GENE DELIVERY USING POLYMERS AND LIPOSOMES$17
P41 · FY2011 · RR · contact PI
Rational Design of Viral-Mimetic Lipid Gene Vectors$315,146
R01 · FY2010 · EB · contact PI
Targeted Drug Delivery to Surface Receptors$270,132
R01 · FY2010 · GM · contact PI
DRUG AND GENE DELIVERY USING POLYMERS AND LIPOSOMES$1,766
P41 · FY2010 · RR · contact PI
Biocompatible Dendritic Polymers for in vivo Applications$429,690
R01 · FY2009 · EB · contact PI
PHARMACEUTICAL SCIENCES AND PHAMOCOGENOMICS$303,262
T32 · FY2009 · GM · contact PI
Targeted Drug Delivery to Surface Receptors$273,014
R01 · FY2009 · GM · contact PI
Pharmaceutical Sciences and Pharmacogenomics$259,938
T32 · FY2009 · GM · contact PI
Targeted Drug Delivery to Surface Receptors$185,000
R01 · FY2009 · GM · contact PI
Pharmacokinetics, Biodistrbution and Biocompatibility Core$145,312
U54 · FY2009 · CA · contact PI
Biocompatible Dendritic Polymers for in vivo Applications$135,591
R01 · FY2009 · EB · contact PI
MATRIX-ATTACHMENT THERAPY: A STRATEGY TO DELIVER 5-FLUOROURACIL TO TUMOR$8,757
P41 · FY2009 · RR · contact PI
DRUG AND GENE DELIVERY USING POLYMERS AND LIPOSOMES$5,857
P41 · FY2009 · RR · contact PI
Biocompatible Dendritic Polymers for in vivo Applications$417,388
R01 · FY2008 · EB · contact PI
Pharmacology of Targeted Therapy to Brain Tumors$364,513
R01 · FY2008 · CA · contact PI
PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICS$301,719
T32 · FY2008 · GM · contact PI
Targeted Drug Delivery to Surface Receptors$272,664
R01 · FY2008 · GM · contact PI
Pharmacokinetics, Biodistrbution and Biocompatibility Core$139,022
U54 · FY2008 · CA · contact PI
ENGINEERING MOTOR PROTEIN TO ENHANCE GENE DELIVERY TO THE NUCLEUS$5,792
P41 · FY2008 · RR · contact PI
MATRIX-ATTACHMENT THERAPY: A STRATEGY TO DELIVER 5-FLUOROURACIL TO TUMOR$5,792
P41 · FY2008 · RR · contact PI
DRUG AND GENE DELIVERY USING POLYMERS AND LIPOSOMES$545
P41 · FY2008 · RR · contact PI
Biocompatible Dendritic Polymers for in vivo Applications$455,536
R01 · FY2007 · EB · contact PI
Pharmacology of Targeted Therapy to Brain Tumors$363,454
R01 · FY2007 · CA · contact PI
Rational Design of Viral-Mimetic Lipid Gene Vectors$355,947
R01 · FY2007 · EB · contact PI
PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICS$301,718
T32 · FY2007 · GM · contact PI
Targeted Drug Delivery to Surface Receptors$269,534
R01 · FY2007 · GM · contact PI
Pharmacokinetics, Biodistrbution and Biocompatibility Core$137,527
U54 · FY2007 · CA · contact PI
MATRIX-ATTACHMENT THERAPY: A STRATEGY TO DELIVER 5-FLUOROURACIL TO TUMOR$8,926
P41 · FY2007 · RR · contact PI
ENGINEERING MOTOR PROTEIN TO ENHANCE GENE DELIVERY TO THE NUCLEUS$8,926
P41 · FY2007 · RR · contact PI
DRUG AND GENE DELIVERY USING POLYMERS AND LIPOSOMES$3,314
P41 · FY2007 · RR · contact PI
Biocompatible Dendritic Polymers for in vivo Applications$492,029
R01 · FY2006 · EB · contact PI
Rational Design of Viral-Mimetic Lipid Gene Vectors$366,578
R01 · FY2006 · EB · contact PI
Pharmacology of Targeted Therapy to Brain Tumors$365,790
R01 · FY2006 · CA · contact PI
Pharmaceutical Sciences and Pharmacogenomics$191,266
T32 · FY2006 · GM · contact PI
Pharmacokinetics, Biodistrbution and Biocompatibility Core$98,781
U54 · FY2006 · CA · contact PI
Targeted Drug Delivery to Surface Receptors$83,829
R01 · FY2006 · GM · contact PI
MATRIX-ATTACHMENT THERAPY: A STRATEGY TO DELIVER 5-FLUOROURACIL TO TUMOR$7,655
P41 · FY2006 · RR · contact PI
ENGINEERING MOTOR PROTEIN TO ENHANCE GENE DELIVERY TO THE NUCLEUS$7,655
P41 · FY2006 · RR · contact PI
DRUG AND GENE DELIVERY USING POLYMERS AND LIPOSOMES$1,802
P41 · FY2006 · RR · contact PI
Rational Design of Viral-Mimetic Lipid Gene Vectors$375,400
R01 · FY2005 · EB
Biocompatible Dendritic Polymers : In Vivo Applications$367,187
R01 · FY2005 · EB
Pharmacology of Targeted Therapy to Brain Tumors$365,362
R01 · FY2005 · CA
Pharmaceutical Sciences and Pharmacogenomics$232,125
T32 · FY2005 · GM
Pharmacokinetics, Biodistrbution and Biocompatibility Core$93,042
U54 · FY2005 · CA
ENGINEERING MOTOR PROTEIN TO ENHANCE GENE DELIVERY TO THE NUCLEUS$6,432
P41 · FY2005 · RR
MATRIX-ATTACHMENT THERAPY: A STRATEGY TO DELIVER 5-FLUOROURACIL TO TUMOR$6,432
P41 · FY2005 · RR
DRUG AND GENE DELIVERY USING POLYMERS AND LIPOSOMES$3,226
P41 · FY2005 · RR
Pharmacology of Targeted Therapy to Brain Tumors$396,324
R01 · FY2004 · CA
Rational Design of Viral-Mimetic Lipid Gene Vectors$375,400
R01 · FY2004 · EB
Biocompatible Dendritic Polymers : In Vivo Applications$356,748
R01 · FY2004 · EB
Targeted Drug Delivery to Surface Receptors$244,850
R01 · FY2004 · GM
Pharmaceutical Sciences and Pharmacogenomics$232,125
T32 · FY2004 · GM
MATRIX-ATTACHMENT THERAPY: A STRATEGY TO DELIVER 5-FU$5,972
P41 · FY2004 · RR
GENE AND DRUG THERAPY TO TREAT CANCER$5,972
P41 · FY2004 · RR
ENGINEERING PROTEIN TO ENHANCE GENE DELIVERY TO NUCLEUS$5,972
P41 · FY2004 · RR
DRUG AND GENE DELIVERY USING POLYMERS AND LIPOSOMES$3,540
P41 · FY2004 · RR
Rational Design of Viral-Mimetic Lipid Gene Vectors$375,400
R01 · FY2003 · EB
Biocompatible Dendritic Polymers : In Vivo Applications$346,301
R01 · FY2003 · EB
Targeted Drug Delivery to Surface Receptors$244,850
R01 · FY2003 · GM
Pharmaceutical Sciences and Pharmacogenomics$193,755
T32 · FY2003 · GM
Biocompatible Dendritic Polymers : In Vivo Applications$360,729
R01 · FY2002 · GM
Targeted Drug Delivery to Surface Receptors$244,850
R01 · FY2002 · GM
Pharmaceutical Sciences and Pharmacogenomics$151,677
T32 · FY2002 · GM
MICROINJECTION INTO CELLS W/ LIPOSOME SYSTEM$0
P41 · FY2002 · RR
GENE THERAPY FOR LUNG DISEASES$273,230
P41 · FY2001 · RR
PHARMACEUTICAL CHEMISTRY AND BIOPHARMACEUTICAL SCIENCES$270,834
T32 · FY2001 · GM
Targeted Drug Delivery to Surface Receptors$234,994
R01 · FY2001 · GM
SYNTHETIC GENE CARRIERS TO TREAT CYSTIC FIBROSIS$222,813
R01 · FY2001 · DK
MICROINJECTION INTO CELLS W/ LIPOSOME SYSTEM$0
P41 · FY2001 · RR
PHARMACEUTICAL CHEMISTRY AND BIOPHARMACEUTICAL SCIENCES$283,042
T32 · FY2000 · GM
SYNTHETIC GENE CARRIERS TO TREAT CYSTIC FIBROSIS$216,412
R01 · FY2000 · DK
SELECTIVE SUPPRESSION OF GENE FUNCTION IN VIVO$22,067
R01 · FY2000 · GM
MICROINJECTION INTO CELLS W/ LIPOSOME SYSTEM$9,880
P41 · FY2000 · RR
GENE THERAPY FOR LUNG DISEASES$136
P41 · FY2000 · RR